[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628228":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DLL3-targeted PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of DLL3-targeted probe and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET\u002FCT), DLL3-targeted PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET\u002FCT), DLL3-targeted PET\u002FCT","Participants will undergo DLL3-Targeted PET\u002FCT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Haojun Chen","86 18659285282","leochen0821@foxmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],118.08187,24.47979,{"lat":43,"lon":42},[46],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100628228","dll3-targeted-petct-in-neuroendocrine-carcinoma-100628228",false,"NCT07458906","DLL3-Targeted PET\u002FCT in Neuroendocrine Carcinoma","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":60,"type":61},60,"ESTIMATED","INTERVENTIONAL",[64],"NA","The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.",[67,68,69],"DLL3-expressing Tumors","PET \u002F CT","Neuroendocrine Cancer",[71,72,69],"DLL3-expressing tumors","PET\u002FCT","2026-03-04",{"date":75,"type":76},"2026-03-09","ACTUAL",{"date":78,"type":76},"2025-12-01",{"date":80,"type":61},"2026-12-31",{"name":5,"class":6},1]